AbbVie Prices $8 Billion Multi-Tranche Senior Notes Offering
ABBV sits 39% above its 52-week low of $164.39.
Summary
AbbVie Inc. has finalized the terms for an $8.0 billion multi-tranche senior notes offering, with maturities ranging from 2028 to 2066.
Key Events · Financing and Capital Events · ABBV
-
Pricing of Senior Notes Offering
AbbVie Inc. priced an $8.0 billion aggregate principal amount of senior notes across seven different tranches.
-
Multi-Tranche Structure
The offering includes both floating rate notes due 2028 and fixed-rate senior notes with maturities ranging from 2028 to 2066, featuring coupons from 3.775% to 5.650%.
-
Finalizes Prior Disclosure
This Free Writing Prospectus finalizes the terms and pricing of the offering that was initiated with a preliminary prospectus supplement filed on February 24, 2026.
Analysis · ABBV · Life Sciences
AbbVie Inc. has finalized the terms for a substantial $8.0 billion senior notes offering, which follows the preliminary prospectus supplement filed yesterday. This significant debt issuance, comprising seven tranches with maturities extending up to 2066, will impact the company's capital structure and financing costs. For a company of AbbVie's scale, this capital raise is a notable event, likely intended for general corporate purposes, including potential refinancing of existing debt, funding operations, or supporting strategic initiatives. The successful pricing of such a large offering demonstrates continued access to capital markets for the pharmaceutical giant.
At the time of this filing, ABBV was trading at $228.64 on NYSE in the Life Sciences sector, with a market capitalization of approximately $403.9B. The 52-week trading range was $164.39 to $244.81. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.